PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway | Zendy

Jian Zhou | Zendy; Kwang Joo Kwak | Zendy; Zuoren Wu | Zendy; Dawei Yang | Zendy; Jing Li | Zendy; Meijia Chang | Zendy; Yuanlin Song | Zendy; Hengshan Zeng | Zendy; L. James Lee | Zendy; Jie Hu | Zendy; Chunxue Bai | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway

Author(s) -

Jian Zhou,

Kwang Joo Kwak,

Zuoren Wu,

Dawei Yang,

Jing Li,

Meijia Chang,

Yuanlin Song,

Hengshan Zeng,

L. James Lee,

Jie Hu,

Chunxue Bai

Publication year - 2018

Publication title -

cellular physiology and biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.486

H-Index - 87

eISSN - 1421-9778

pISSN - 1015-8987

DOI - 10.1159/000491071

Subject(s) - gefitinib , biology , gene knockdown , cancer research , oncogene , cell cycle , rna interference , epidermal growth factor receptor , cell , apoptosis , cancer , rna , gene , biochemistry , genetics

Tyrosine kinase inhibitor gefitinib significantly improves the survival of patients with non-small-cell lung cancer (NSCLC) by inhibiting epidermal growth factor receptor (EGFR) tyrosine kinase. However, patients eventually develop resistance to gefitinib through uncharacterized mechanisms. It is known that plasminogen activator urokinase receptor (PLAUR) plays an important role in cell proliferation, migration and apoptosis. However, the role of PLAUR, particularly exosomal PLAUR in gefitinib resistance in NSCLC has not been reported. The aim of this study is to determine the relationship between PLAUR and gefitinib resistance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research